Study Details

A Study of ASP8302 in participants with Underactive Bladder

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred). ID

The unique identification code given to each clinical study upon registration at

Astellas Study ID

The unique identification code given by the study sponsor.


EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).



Underactive Bladder


These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2


18 years - N/A


Female & Male




A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


Trial Dates

Nov 2018 - Apr 2020


Double (Participant, Investigator)

Enrollment number


A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2a, Proof-of-Concept Study of ASP8302 in Subjects with Underactive Bladder

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP8302 in participants with Underactive Bladder? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.


Site DE49001

Duisburg, Germany

Site NL31004

Zwolle, Netherlands

Site JP81013

Shizuoka, Japan

Site DE49002

Duisburg, Germany

Site JP81015

Sapporo, Japan

Site SK42101

Nitra, Slovakia

Site NL31002

Maastricht, Netherlands

Site JP81012

Kurashiki, Japan

Site JP81008

Obu, Japan

Site UK44002

Bristol, United Kingdom

Site JP81001

Shimotsuga-gun, Japan

Site SK42103

Kosice, Slovakia

Site JP81010

Saga, Japan

Site UK44003

Cambridge, United Kingdom

Site DE49004

Gronau, Germany

Site PL48004

Myslowice, Poland

Site PL48002

Szczecin, Poland

Site UK44001

Sheffield, United Kingdom

Site DE49003

Moenchengladbach, Germany

Site JP81002

Kobe, Japan

Site JP81006

Asahikawa, Japan

Site JP81009

Nagoya, Japan

Site PL48001

Warsaw, Poland

Site JP81004

Kumamoto, Japan

Site PL48003

Piaseczno, Poland

Site JP81011

Osakasayama, Japan

Site NL31003

Eindhoven, Netherlands

Site JP81005

Sapporo, Japan

Site SK42102

Trencin, Slovakia

Site JP81003

Fukuoka, Japan

Site JP81007

Yoshida-gun, Japan

Site NL31001

Rotterdam, Netherlands